ExodusPoint Capital Management LP Sells 843,055 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

ExodusPoint Capital Management LP trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 81.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 191,283 shares of the company's stock after selling 843,055 shares during the period. ExodusPoint Capital Management LP's holdings in Elanco Animal Health were worth $2,316,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC raised its stake in shares of Elanco Animal Health by 28.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock valued at $124,000 after acquiring an additional 2,264 shares during the last quarter. DDD Partners LLC acquired a new stake in Elanco Animal Health during the 4th quarter valued at $5,974,000. Geode Capital Management LLC raised its position in Elanco Animal Health by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock valued at $115,623,000 after purchasing an additional 65,303 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock worth $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Elanco Animal Health by 19.2% during the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company's stock worth $58,875,000 after purchasing an additional 646,522 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Trading Down 0.8 %

NYSE ELAN traded down $0.07 during trading hours on Friday, hitting $8.64. The company's stock had a trading volume of 5,847,865 shares, compared to its average volume of 4,897,100. Elanco Animal Health Incorporated has a twelve month low of $8.03 and a twelve month high of $18.80. The firm has a market capitalization of $4.29 billion, a P/E ratio of 21.60, a PEG ratio of 2.50 and a beta of 1.44. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average of $10.59 and a 200 day moving average of $12.03.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm posted $0.08 EPS. The business's revenue was down 1.4% on a year-over-year basis. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the acquisition, the director now owns 101,459 shares in the company, valued at approximately $1,105,903.10. This trade represents a 10.93 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.57% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Piper Sandler reduced their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, UBS Group reduced their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.